The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer
Andrew Chow,Fathema Z Uddin,Michael Liu,Anton Dobrin,Barzin Y Nabet,Levi Mangarin,Yonit Lavin,Hira Rizvi,Sam E Tischfield,Alvaro Quintanal-Villalonga,Joseph M Chan,Nisargbhai Shah,Viola Allaj,Parvathy Manoj,Marissa Mattar,Maximiliano Meneses,Rebecca Landau,Mariana Ward,Amanda Kulick,Charlene Kwong,Matthew Wierzbicki,Jessica Yavner,Jacklynn Egger,Shweta S Chavan,Abigail Farillas,Aliya Holland,Harsha Sridhar,Metamia Ciampricotti,Daniel Hirschhorn,Xiangnan Guan,Allison L Richards,Glenn Heller,Jorge Mansilla-Soto,Michel Sadelain,Christopher A Klebanoff,Matthew D Hellmann,Triparna Sen,Elisa de Stanchina,Jedd D Wolchok,Taha Merghoub,Charles M Rudin
DOI: https://doi.org/10.1016/j.immuni.2022.12.001
IF: 32.4
2023-01-10
Immunity
Abstract:Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we comprehensively profiled CD39 expression in human lung cancer. CD39 expression enriched for CD8+ T cells with features of exhaustion, tumor reactivity, and clonal expansion. Flow cytometry of 440 lung cancer biospecimens revealed weak association between CD39+ CD8+ T cells and tumoral features, such as programmed death-ligand 1 (PD-L1), tumor mutation burden, and driver mutations. Immune checkpoint blockade (ICB), but not cytotoxic chemotherapy, increased intratumoral CD39+ CD8+ T cells. Higher baseline frequency of CD39+ CD8+ T cells conferred improved clinical outcomes from ICB therapy. Furthermore, a gene signature of CD39+ CD8+ T cells predicted benefit from ICB, but not chemotherapy, in a phase III clinical trial of non-small cell lung cancer. These findings highlight CD39 as a proxy of tumor-reactive CD8+ T cells in human lung cancer.